



FOR IMMEDIATE RELEASE

CONTACT:

VelQuest:

Joan Milne

Phone: 508-497-9911

Joan.Milne@velquest.com

www.velquest.com

Forest Laboratories implements VelQuest's Automated Compliance Technology

VelQuest Corporation, Hopkinton, MA, March 16, 2004

VelQuest, the innovator of a paperless Compliance Management System using electronic Notebooks and Forest Laboratories Ireland Ltd., Dublin, Ireland, a division of Forest Laboratories Europe which is a wholly owned subsidiary of Forest Laboratories Inc, New York, USA, a highly successful developer, manufacturer and marketer of prescription pharmaceuticals announced today that Forest Laboratories Ireland Ltd has implemented VelQuest's SmartLab™ technology as part of their overall strategic plan.

"We are excited to be working with VelQuest towards eliminating tedious paperwork in our Quality Control Operation" says Francis Bates, Quality Technical Services Manager. "We have seen significant improvement in efficiencies and a reduction in cycle times of releasing product to customers using VelQuest's solution."

Louis W. Yu, Executive Director Corporate Quality and Compliance said, "VelQuest's Automated Compliance e-Notebooks will enable us to integrate our first time right Quality Program and reduce cycle times for internal and FDA Audits because our Control data is available instantly."

The VelQuest SmartLab™ application is an innovative solution to a fundamental problem - pharmaceutical development and quality control records are frequently paper-based and data auditing related activities can consume up to 70% of valuable human resource in laboratories. VelQuest's Patented Technology interacts with scientists in real time and allows the capture of data directly from human observations, devices such as balances and pH meters, and PC-controlled instruments, driven by SOP's and Test Methods.

"We are extremely pleased that Forest Laboratories Ltd, has deployed our system in their Quality Operations in Dublin," said Gordon Johnston, President European Operations of VelQuest, Inc. "We believe that Forest's use of our SmartLab™ application, demonstrates the value of our technology to increasing productivity and compliance confidence in regulated laboratories."

About VelQuest Corporation

The VelQuest electronic Process Management & Compliance (ePMC™) Operating System is an innovative software platform designed to provide the foundation for compliance-based activities in the life science markets. The software embraces the FDA's "cGMPs for the 21st Century: A Risk Based Approach" initiative, and supports the company's SmartLab™ Applications for a fully compliant electronic laboratory, SmartShell™ 21 CFR Part 11 remediation software, as well as planned product line extensions.

Founded in January, 1999, VelQuest Corporation provides a growing suite of unique products to help transform regulated industries from labor-intensive, paper-based operations to automated, efficient systems, with greater confidence in their compliance than ever before possible.

VelQuest, SmartLab, SmartShell and ePMC are trademarks of VelQuest Corporation.

About Forest Laboratories and Its Products

Forest Laboratories develops, manufactures and markets pharmaceutical products principally in the United States and Europe. Forest's primary therapeutic markets include central nervous system disorders, hypertension and pulmonary disorders. Forest is currently developing additional compounds in these areas as well as in pain management and gastrointestinal disorders. Forest's principal products include Lexapro™, a selective serotonin reuptake inhibitor (SSRI) for the treatment of depression; Celexa™, also for depression; Benicar®,* an angiotensin receptor blocker (ARB) for the treatment of hypertension; and Aerobid®, a metered dose inhaler for treating asthma.

Except for the historical information contained herein, this release contains forward looking statements that involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2003 and the quarterly report on Form 10-Q for the period ended June 30, 2003.